

Accepted Manuscript

Therapeutic Approach to Adult Fibrotic Lung Diseases

Ayodeji Adegunsoye, MD, Mary E. Streck, MD

PII: S0012-3692(16)53666-6

DOI: [10.1016/j.chest.2016.07.027](https://doi.org/10.1016/j.chest.2016.07.027)

Reference: CHEST 590

To appear in: *CHEST*


Received Date: 29 July 2015

Revised Date: 20 July 2016

Accepted Date: 21 July 2016

Please cite this article as: Adegunsoye A, Streck ME, Therapeutic Approach to Adult Fibrotic Lung Diseases, *CHEST* (2016), doi: 10.1016/j.chest.2016.07.027.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



RECENT ADVANCES IN CHEST MEDICINE

THERAPEUTIC APPROACH TO ADULT FIBROTIC LUNG DISEASES

Ayodeji Adegunsoye MD, Mary E. Streck, MD

aadegunsoye@medicine.bsd.uchicago.edu

mstrek@medicine.bsd.uchicago.edu

Section of Pulmonary and Critical Medicine
University of Chicago Medicine
5841 South Maryland MC 6076
Chicago, IL 60637

Correspondence:

Deji Adegunsoye, MD, 5841 South Maryland MC 6076 Chicago, IL 60637

Conflict of Interest: Dr. Streck has received institutional funding for IPF research from Bristol-Myers Squibb, Genentech, Gilead and MedImmune and she serves on a data monitoring committee for Boehringer Ingelheim and participated in an advisory committee for Genentech.

Disclosures: Dr. Adegunsoye is supported by a National Institute of Health grant (T32 HL 07605).

Word Count:

Abstract: **205**

Manuscript: **5,380**

Download English Version:

<https://daneshyari.com/en/article/5952115>

Download Persian Version:

<https://daneshyari.com/article/5952115>

[Daneshyari.com](https://daneshyari.com)